Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.98 USD
Change Today -0.0489 / -0.33%
Volume 128.0K
NVIV On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 2:02 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$14.97
Previous Close
$15.03
Day High
$15.10
Day Low
$14.75
52 Week High
04/17/15 - $19.68
52 Week Low
09/10/14 - $1.86
Market Cap
397.9M
Average Volume 10 Days
306.2K
EPS TTM
$-1.07
Shares Outstanding
26.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injury (SCI). The company is developing a Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold for the implantation at the site of injury within a spinal cord contusion; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Boston Children's Hospital and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

31 Employees
Last Reported Date: 03/11/15
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chairman of the Board and Chief Executive Off...
Total Annual Compensation: $532.3K
Chief Financial Officer
Total Annual Compensation: $369.1K
Chief Compliance Officer, Senior Vice Preside...
Total Annual Compensation: $171.1K
Chief Scientific Officer
Total Annual Compensation: $253.7K
Compensation as of Fiscal Year 2014.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. announced a one-month post-implant update for the third study patient and a six-month post-implant update for the second study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with complete acute spinal cord injury. In the time between implantation and the one-month post-injury assessment of the third study patient, the patient improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. The patient has regained sacral sensation with improved bladder function. Historically, fewer than 4% of patients with a high thoracic neurologic level of injury convert from AIS A to AIS B in the first month after injury. There were no reported serious adverse events associated with the Neuro-Spinal Scaffold. The second patient demonstrated marked improvement in sensory function with partial sensation present five dermatome levels lower on the right side compared to the three-month assessment. This translates to regaining partial sensation from the lower ribs to the hip on the right. The patient continues to make meaningful progress in activities of daily living.

InVivo Therapeutics Holdings Corp.(NasdaqCM:NVIV) added to Russell 2000 Index

InVivo Therapeutics Holdings Corp. will be added to Russell 2000 Index

InVivo Therapeutics Holdings Corp.(NasdaqCM:NVIV) added to Russell 3000 Index

InVivo Therapeutics Holdings Corp. will be added to the Russell 3000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $14.98 USD -0.0489

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 38.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.